

David A Morrow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6983843/david-a-morrow-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

282
papers

33,161
citations

83
h-index

180
g-index

315
ext. papers

39,836
ext. citations

9.3
avg, IF

7.05
L-index

#	Paper	IF	Citations
282	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
281	Epidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network.. <i>Journal of Cardiac Failure</i> , 2022 ,	3.3	1
280	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.. <i>American Heart Journal</i> , 2022 , 246, 136-136	4.9	1
279	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022 , 243, 147-157	4.9	1
278	Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry.. <i>Journal of the American Heart Association</i> , 2022 , e024451	6	0
277	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2021 ,	16.7	1
276	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008477	7.6	0
275	Cardiogenic Shock After Acute Myocardial Infarction: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1840-1850	27.4	13
274	Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. <i>Circulation: Heart Failure</i> , 2021 ,	7.6	2
273	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of Cardiovascular Computed Tomography</i> , 2021 ,	2.8	6
272	Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2674-2676	15.4	
271	Closing the Gap: Insights into the Epidemiology of Heart Failure Care from the Critical Care Cardiology Trials Network. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1146-1147	3.3	1
270	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021412	6	0
269	De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1073-1083	3.3	3
268	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021 , 144, e368-e454	16.7	16
267	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021 , 144, e368-e454	16.7	30
266	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2021 , 78, e187-e285	15.1	28

265	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2218-2261	15.1	2
264	Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation</i> , 2021 , 143, 2332-2342	16.7	57
263	SPOT the DIAGNOSIS. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 240	4.3	
262	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021 , 42, 1698-1708	9.5	11
261	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2P-TIMI 50. <i>Journal of the American Heart Association</i> , 2021 , 10, e018673	6	3
260	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , 2021 , 10, e017401	6	6
259	The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. <i>Critical Care Medicine</i> , 2021 , 49, 1293-1302	1.4	10
258	Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021 , 4, e218828	10.4	43
257	Epidemiology and causes of cardiogenic shock. <i>Current Opinion in Critical Care</i> , 2021 , 27, 401-408	3.5	6
256	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , 2021 , 144, 249-251	16.7	0
255	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 675-681	5.1	3
254	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation) Investigators. <i>American Heart Journal</i> , 2021 , 233, 1-5	4.9	2
253	Biomarkers for Risk Assessment in Atrial Fibrillation. <i>Clinical Chemistry</i> , 2021 , 67, 87-95	5.5	8
252	Potential growth in cardiogenic shock research through an international registry collaboration: the merits and challenges of a Hub-of-Spokes model. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 3-5	4.3	0
251	Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	7
250	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , 2021 , 143, 685-695	16.7	3
249	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007034	7.6	8
248	Trends in Therapy and Outcomes Associated With Respiratory Failure in Patients Admitted to the Cardiac Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 2021 , 8850666211003489	3.3	2

247	Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1309-1317	15.1	8
246	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2573-2581	14.6	0
245	Cardiac myosin-binding protein C as a biomarker of acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 963-965	4.3	0
244	N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort. <i>Journal of the American Heart Association</i> , 2021 , e022913 ⁶		2
243	Utilization and outcomes of early respiratory support in 6.5 million acute heart failure hospitalizations. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 72-80	4.6	6
242	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 787-793	16.2	11
241	A current review of COVID-19 for the cardiovascular specialist. <i>American Heart Journal</i> , 2020 , 226, 29-44	4.9	66
240	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e015331	6	16
239	Left ventricle unloading strategies in ECMO: A single-center experience. <i>Journal of Cardiac Surgery</i> , 2020 , 35, 1514-1524	1.3	3
238	Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. <i>JAMA Cardiology</i> , 2020 , 5, 703-708	16.2	35
237	American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006967	5.8	31
236	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1095-1106	15.1	12
235	Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. <i>American Heart Journal</i> , 2020 , 222, 8-14	4.9	7
234	COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. <i>JACC Basic To Translational Science</i> , 2020 , 5, 518-536	8.7	162
233	Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population. <i>American Heart Journal</i> , 2020 , 224, 57-64	4.9	29
232	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020 , 25, 124-132	3.3	15
231	Percutaneous right ventricular assist device-supported ventricular tachycardia ablation in a patient with severe right ventricular dysfunction. <i>Heart Rhythm Case Reports</i> , 2020 , 6, 72-76	1	
230	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2020 ,	3.9	5

229	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020 , 219, 1-8	4.9	11
228	Positive Pressure Ventilation in Cardiogenic Shock: Review of the Evidence and Practical Advice for Patients With Mechanical Circulatory Support. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 300-312	3.8	10
227	Initiation of Angiotensin-Nepriylsin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. <i>JAMA Cardiology</i> , 2020 , 5, 202-207	16.2	29
226	Respiratory support in acute heart failure with preserved vs reduced ejection fraction. <i>Clinical Cardiology</i> , 2020 , 43, 320-328	3.3	3
225	Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1084-1101	15.1	20
224	Angiotensin Receptor-Nepriylsin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1034-1048	15.1	19
223	Angiotensin-Nepriylsin Inhibition in Black Americans: Data From the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 859-866	7.9	4
222	Advanced Respiratory Support in the Contemporary Cardiac ICU 2020 , 2, e0182		7
221	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. <i>Circulation</i> , 2020 , 142, 2095-2106	16.7	83
220	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 834-843	7.9	6
219	Which patients with acute coronary syndrome need the cardiac intensive care unit: tuning the tools for risk stratification. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 543-545	4.3	
218	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2548-2549	27.4	64
217	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020 , 5, 1255-1262	16.2	12
216	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020 , 5, 1236-1244	16.2	15
215	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection?. <i>Clinical Chemistry</i> , 2020 , 66, 1146-1149	5.5	3
214	Practice pattern of use of high sensitivity troponin in the outpatient settings. <i>Clinical Cardiology</i> , 2020 , 43, 1573-1578	3.3	1
213	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. <i>EClinicalMedicine</i> , 2020 , 26, 100504	11.3	34
212	Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020 , 230, 93-97	4.9	7

211	COVID-19 and Disruptive Modifications to Cardiac Critical Care Delivery: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 72-84	15.1	32
210	Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 2048872620919947	4.3	4
209	Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for Mortality. <i>Journal of the American Heart Association</i> , 2019 , 8, e013675	6	26
208	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. <i>European Heart Journal</i> , 2019 , 40, 3345-3352	9.5	40
207	Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non-ST Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2019 , 8, e011444	6	4
206	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019 , 24, 159-161	3.3	3
205	Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005618	5.8	98
204	RESPONSE: Transition to Early Career in Critical Care Cardiology: Know Who You Want to Be. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1730	15.1	
203	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019 , 139, 2285-2288	16.7	78
202	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1059-1077	15.1	52
201	Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTEMI-ACS. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1084-1092	5.9	7
200	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. <i>Critical Pathways in Cardiology</i> , 2019 , 18, 1-4	1.3	2
199	Editor's Choice-Prospective registry of cardiac critical illness in a modern tertiary care Cardiac Intensive Care Unit. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 755-761	4.3	15
198	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851
197	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1057-1068	15.1	21
196	Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. <i>Circulation</i> , 2019 , 140, 1661-1678	16.7	90
195	Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units: The Critical Care Cardiology Trials Network Prospective North American Multicenter Registry of Cardiac Critical Illness. <i>JAMA Cardiology</i> , 2019 , 4, 928-935	16.2	63
194	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>Circulation: Heart Failure</i> , 2019 , 12, e006635	7.6	19

193	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 3013-3022	15.1	30
192	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 382-391	3	7
191	Angiotensin-Nepriylsin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019 , 380, 539-548	59.2	446
190	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019 , 139, 760-771	16.7	54
189	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 353-360	5.1	6
188	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 [°] P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 2048872619883354	4.3	2
187	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018 , 137, 961-972	16.7	175
186	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1021-1034	15.1	122
185	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 473-480	16.2	21
184	Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018 , 198, 145-151	4.9	42
183	Validation of the Seattle angina questionnaire in women with ischemic heart disease. <i>American Heart Journal</i> , 2018 , 201, 117-123	4.9	17
182	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 454-458	6.7	19
181	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018 , 137, 684-692	16.7	10
180	De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock. <i>European Journal of Heart Failure</i> , 2018 , 20, 621-622	12.3	
179	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2231-2264	15.1	1179
178	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018 , 138, e618-e651	16.7	865
177	Fourth Universal Definition of Myocardial Infarction (2018). <i>Global Heart</i> , 2018 , 13, 305-338	2.9	124
176	RESPONSE: Training in Critical Care Cardiology: Navigating a Field in Transition. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1174-1175	15.1	1

175	Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome. <i>Journal of Critical Care</i> , 2018 , 48, 26-31	4	7
174	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018 , 41, 577-585	14.6	16
173	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018 , 7, e009260	6	7
172	Positive Pressure Ventilation in the Cardiac Intensive Care Unit. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1532-1553	15.1	59
171	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018 , 39, 3810-3820	9.5	18
170	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , 2018 , 41, 1510-1515	14.6	13
169	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018 , 138, 1963-1973	16.7	23
168	Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 18-25	4.3	23
167	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 [®] P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 164-172	4.3	7
166	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 911-921	15.1	111
165	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). <i>Circulation</i> , 2017 , 135, 1911-1921	16.7	43
164	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 962-969	6.7	19
163	Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	20
162	Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017 , 376, 2053-2064	59.2	438
161	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 [®] P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017 , 63, 307-315	5.5	16
160	Soluble interleukin-13 α 1: a circulating regulator of glucose. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017 , 313, E663-E671	6	4
159	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States: An American Heart Association Acute Cardiac Care Committee and American College of Cardiology Critical Care Cardiology Working Group Cross-Sectional Survey. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, e003864	5.8	20
158	Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 108-116	4.3	12

157	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , 2016 , 134, 861-71	16.7	34
156	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016 , 134, 304-13	16.7	102
155	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2 [°] P-TIMI 50 Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2157-2164	5	26
154	Care Setting Intensity and Outcomes After Emergency Department Presentation Among Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	4
153	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2 [°] P-TIMI 50). <i>American Journal of Cardiology</i> , 2016 , 117, 1055-8	3	4
152	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 [°] P-TIMI 50). <i>Circulation</i> , 2016 , 133, 207-1007	16.7	120
151	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 322-323	15.1	11
150	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	76
149	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1591-9	27.4	144
148	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 989-998	16.2	59
147	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 999-1006	16.2	45
146	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 [°] P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
145	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 431-40	4.3	13
144	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. <i>American Heart Journal</i> , 2015 , 169, 622-630.e6	4.9	27
143	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015 , 17, 32-7	3.9	40
142	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , 2015 , 131, 1047-53	16.7	59
141	The unmet need for addressing cardiac issues in intensive care research. <i>Critical Care Medicine</i> , 2015 , 43, 128-34	1.4	13
140	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015 , 132, e121-2	16.7	45

139	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 [°] P-TIMI 50. <i>Circulation</i> , 2015 , 132, 1871-9	16.7	30
138	Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial. <i>Clinical Cardiology</i> , 2015 , 38, 469-75	3.3	15
137	Efficacy and safety of vorapaxar as approved for clinical use in the United States. <i>Journal of the American Heart Association</i> , 2015 , 4, e001505	6	55
136	Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1644-53	15.1	64
135	Lipoprotein(a) for risk assessment in patients with established coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 520-7	15.1	119
134	Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. <i>Clinical Cardiology</i> , 2014 , 37, 350-6	3.3	10
133	Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. <i>Clinical Chemistry</i> , 2014 , 60, 158-64	5.5	59
132	Death or revascularization among nonadmitted ED patients with low-positive vs negative troponin T results. <i>American Journal of Emergency Medicine</i> , 2014 , 32, 923-8	2.9	
131	Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 [°] P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2309-17	15.1	37
130	New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 [°] P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2318-26	15.1	29
129	ECG morphological variability in beat space for risk stratification after acute coronary syndrome. <i>Journal of the American Heart Association</i> , 2014 , 3, e000981	6	11
128	Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo. <i>American Journal of Cardiology</i> , 2014 , 114, 17-23	3	16
127	Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 310-6	5.1	9
126	Unstable angina: is it time for a requiem?. <i>Circulation</i> , 2013 , 127, 2452-7	16.7	133
125	Organization and staffing practices in US cardiac intensive care units: a survey on behalf of the American Heart Association Writing Group on the Evolution of Critical Care Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 3-8	4.3	35
124	Efficacy and safety of vorapaxar in patients with prior ischemic stroke. <i>Stroke</i> , 2013 , 44, 691-8	6.7	80
123	Evaluation of a clinical pathway for sedation and analgesia of mechanically ventilated patients in a cardiac intensive care unit (CICU): The Brigham and Women [®] Hospital Levine CICU sedation pathways. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 299-305	4.3	16
122	Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG [®] . <i>Clinical Chemistry</i> , 2013 , 59, 1205-14	5.5	15

121	Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. <i>Circulation</i> , 2013 , 127, 1522-9, 1529e1-6	16.7	208
120	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction). <i>Circulation</i> , 2012 , 126, 1494-502	16.7	129
119	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 ^o P-TIMI 50 trial. <i>Lancet, The</i> , 2012 , 380, 1317-24	4 ^o	177
118	Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 332-8	15.1	46
117	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
116	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2012 , 366, 1404-13	59.2	694
115	Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. <i>Circulation</i> , 2012 , 126, 1408-28	16.7	171
114	Third universal definition of myocardial infarction. <i>Circulation</i> , 2012 , 126, 2020-35	16.7	2259
113	Novel biomarkers in cardiovascular disease: research tools or ready for personalized medicine?. <i>Cardiology in Review</i> , 2012 , 20, 111-7	3.2	8
112	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , 2012 , 98, 786-91	5.1	29
111	Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. <i>Clinical Chemistry</i> , 2012 , 58, 257-66	5.5	115
110	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2551-67	9.5	2064
109	ST-Segment Elevation Myocardial Infarction 2012 , 1111-1177		4
108	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). <i>American Heart Journal</i> , 2011 , 161, 1417-25	4.9	43
107	Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial). <i>American Journal of Cardiology</i> , 2011 , 108, 1373-81	3	12
106	Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 203-10	9.4	103
105	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>European Heart Journal</i> , 2011 , 32, 697-705	9.5	64
104	Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. <i>Heart</i> , 2011 , 97, 1782-7	5.1	43

103	Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. <i>Circulation</i> , 2010 , 122, 455-62	16.7	88
102	Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. <i>Circulation</i> , 2010 , 121, 2681-91	16.7	78
101	Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2503-12	27.4	753
100	Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. <i>Diabetes Care</i> , 2010 , 33, 1163-8	14.6	60
99	Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. <i>Clinical Chemistry</i> , 2010 , 56, 941-3	5.5	103
98	Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). <i>Circulation</i> , 2010 , 121, 1809-17	16.7	49
97	One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010 , 31, 2097-102	9.5	5
96	Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010 , 31, 2103-10	9.5	33
95	B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1189-1196	15.1	61
94	Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2118-24	15.1	105
93	Novel biomarkers in cardiovascular disease: update 2010. <i>American Heart Journal</i> , 2010 , 160, 583-94	4.9	115
92	Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. <i>Circulation</i> , 2009 , 119, 2032-9	16.7	120
91	Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 424-30	9.4	120
90	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an	16.7	137
89	Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. <i>Clinical Chemistry</i> , 2009 , 55, 265-73	5.5	45
88	SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiology</i> , 2009 , 5, 435-42	1.3	13
87	Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 344-53	5.8	95
86	Spectral energy of ECG morphologic differences to predict death. <i>Cardiovascular Engineering (Dordrecht, Netherlands)</i> , 2009 , 9, 18-26		6

85	A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 359-64	5.1	59
84	Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. <i>American Heart Journal</i> , 2009 , 158, 386-91	4.9	71
83	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. <i>American Heart Journal</i> , 2009 , 158, 335-341	4.9	157
82	Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1510-6	15.1	39
81	Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1510-6	15.1	135
80	Evaluation of high-sensitivity assays for cardiac troponin. <i>Clinical Chemistry</i> , 2009 , 55, 5-8	5.5	68
79	Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. <i>European Heart Journal</i> , 2009 , 30, 162-9	9.5	187
78	Defining a role for novel biomarkers in acute coronary syndromes. <i>Clinical Chemistry</i> , 2008 , 54, 1424-31	5.5	20
77	Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2422-9	15.1	16
76	Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. <i>American Heart Journal</i> , 2008 , 155, 49-55	4.9	135
75	Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008 , 1, 107-15	5.8	36
74	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. <i>European Heart Journal</i> , 2008 , 29, 1096-102	9.5	138
73	Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. <i>Circulation</i> , 2008 , 117, 1936-44	16.7	238
72	The future of biomarkers in the management of patients with acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2008 , 23, 309-14	2.1	12
71	Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized, controlled trial. <i>Circulation</i> , 2007 , 116, 1647-57	16.7	360
70	Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2256-63	15.1	27
69	Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2117-24	15.1	122
68	Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). <i>American Journal of Cardiology</i> , 2007 , 99, 344-8	3	8

67	Ranolazine in patients with angina and coronary artery disease. <i>Current Cardiology Reports</i> , 2007 , 9, 272-8.2	4.2	12
66	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. <i>Clinical Chemistry</i> , 2007 , 53, 552-74	5.5	326
65	National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. <i>Clinical Chemistry</i> , 2007 , 53, 2086-96	5.5	201
64	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. <i>Clinical Chemistry</i> , 2007 , 53, 547-51	5.5	168
63	Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. <i>Circulation</i> , 2007 , 115, 3071-8	16.7	111
62	Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. <i>Circulation</i> , 2007 , 115, 1528-36	16.7	262
61	Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1775-83	27.4	372
60	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. <i>Point of Care</i> , 2007 , 6, 215-222	0.4	5
59	Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (EXTRACT-TIMI 25) trial. <i>American Heart Journal</i> , 2007 , 154, 1078-84, 1084 e1	4.9	17
58	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. <i>Circulation</i> , 2007 , 115, e356-75	16.7	255
57	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007 , 28, 2077-86	9.5	143
56	Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006 , 8, 13-21	2.1	
55	Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. <i>Circulation</i> , 2006 , 113, e72-5	16.7	83
54	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. <i>Future Cardiology</i> , 2006 , 2, 85-91	1.3	1
53	Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2006 , 354, 1477-88	59.2	465
52	Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. <i>Circulation</i> , 2006 , 114, 550-7	16.7	148
51	Prognostic Value of B-Type Natriuretic Peptide in Unstable Coronary Artery DiseaseReply. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1895	27.4	
50	Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. <i>Circulation</i> , 2006 , 114, 281-8	16.7	239

49	Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. <i>Circulation</i> , 2006 , 113, 2128-34; discussion 2151	16.7	153
48	Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , 2006 , 113, 1745-52	16.7	192
47	Prevalence and determinants of troponin T elevation in the general population. <i>Circulation</i> , 2006 , 113, 1958-65	16.7	320
46	Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1553-8	15.1	41
45	A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2364-73	15.1	106
44	Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2326-31	15.1	128
43	Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. <i>American Heart Journal</i> , 2006 , 151, 1186.e1-9	4.9	56
42	A Multimarker Approach to Evaluation of Patients With Acute Coronary Syndrome 2006 , 545-558		1
41	Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. <i>European Heart Journal</i> , 2005 , 26, 682-8	9.5	50
40	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E-TIMI-25). <i>American Heart Journal</i> , 2005 , 149, 817-26	4.9	71
39	Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. <i>American Heart Journal</i> , 2005 , 149, 846-50	4.9	43
38	C-reactive protein levels and outcomes after statin therapy. <i>New England Journal of Medicine</i> , 2005 , 352, 20-8	59.2	1802
37	Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1644-8	15.1	189
36	Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1417-24	15.1	99
35	Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2866-71	27.4	156
34	Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). <i>American Journal of Cardiology</i> , 2005 , 96, 1284-9	3	73
33	Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.	16.7	53
32	Preprocedural C-reactive protein for risk prediction before percutaneous coronary intervention (PCI): a US perspective. <i>Clinical Chemistry</i> , 2004 , 50, 1489-91	5.5	2

31	The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004 , 25, 1139-45	9.5	15
30	Troponins in acute coronary syndromes. <i>Progress in Cardiovascular Diseases</i> , 2004 , 47, 177-88	8.5	37
29	Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). <i>American Journal of Cardiology</i> , 2004 , 94, 774-6	3	20
28	Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 564-8	15.1	99
27	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 335-9	15.1	171
26	Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1988-95	15.1	270
25	Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2004 , 346, 119-28	6.2	32
24	Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. <i>American Heart Journal</i> , 2004 , 148, 173-80	4.9	20
23	The search for a biomarker of cardiac ischemia. <i>Clinical Chemistry</i> , 2003 , 49, 537-9	5.5	67
22	Troponins in acute coronary syndromes. <i>Seminars in Vascular Medicine</i> , 2003 , 3, 363-74		7
21	Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1264-72	15.1	338
20	Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 7-16	15.1	130
19	Soluble CD40L: risk prediction after acute coronary syndromes. <i>Circulation</i> , 2003 , 108, 1049-52	16.7	330
18	Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. <i>Clinical Chemistry</i> , 2003 , 49, 1396-8	5.5	47
17	Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2002 , 89, 463-5	3	133
16	Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , 2002 , 90, 303-5	3	63
15	Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. <i>Circulation</i> , 2002 , 105, 1760-3	16.7	562
14	Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?. <i>Circulation</i> , 2002 , 106, 2868-70	16.7	91

13	Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. <i>Circulation</i> , 2002 , 106, 202-7	16.7	104
12	Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Reteplase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 71-7	15.1	119
11	Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications. <i>Cardiovascular Toxicology</i> , 2001 , 1, 105-10	3.4	14
10	Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 2405-12	27.4	451
9	The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2001 , 345, 1014-21	59.2	1046
8	A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. <i>Lancet, The</i> , 2001 , 358, 1571-5	40	207
7	Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis in Myocardial Infarction (TIMI) 11B Substudy. <i>Clinical Chemistry</i> , 2000 , 46, 453-460	5.5	102
6	TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. <i>Circulation</i> , 2000 , 102, 2031-7	16.7	1067
5	Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1812-7	15.1	187
4	Where Are we with Vitamin E?. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 209-214	5.1	3
3	C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1460-5	15.1	626
2	Hepatotoxicity associated with methotrexate therapy in a dog. <i>Journal of Small Animal Practice</i> , 1982 , 23, 659-666	1.6	10
1	Moving toward Personalized Medicine205-227		